Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Compass Therapeutics ( (CMPX) ) is now available.
Compass Therapeutics reported its second quarter 2025 financial results and provided updates on its clinical programs. The company observed promising results in its ongoing trials, including fewer deaths in the Phase 2/3 study of tovecimig for biliary tract cancer, and significant tumor reductions in the Phase 1 study of CTX-8371 for lung and breast cancer. The company plans to expand these trials and expects to file an IND for CTX-10726 in late 2025. Despite a net loss increase, Compass maintains a strong cash position, ensuring operations into 2027.
The most recent analyst rating on (CMPX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Compass Therapeutics stock, see the CMPX Stock Forecast page.
Spark’s Take on CMPX Stock
According to Spark, TipRanks’ AI Analyst, CMPX is a Neutral.
Compass Therapeutics’ stock is moderately attractive, driven by strong market momentum and strategic leadership changes. However, significant operational losses, negative cash flows, and lack of current profitability weigh down the financial performance score. While technical indicators are positive, valuation remains a concern due to the negative P/E ratio.
To see Spark’s full report on CMPX stock, click here.
More about Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing proprietary antibody-based therapeutics.
Average Trading Volume: 811,888
Technical Sentiment Signal: Buy
Current Market Cap: $373.4M
See more data about CMPX stock on TipRanks’ Stock Analysis page.